Search PubMed⌕ Search

Biomedical subjects

D R Abernethy

Publications and source records attributed to D R Abernethy.

206 records · Page 12Linked to original sources

Is volume of distribution at steady state a meaningful kinetic variable?

Pharmacokinetic volumes of distribution (Vd) are commonly calculated either by the steady-state method (Vdss) or the area method (Vdarea). Vdss is traditionally perceived as the least biased and most reliable indicator of the extent of distribution, but Vdss in fact has far greater practical and theoretical limitation than does Vdarea. After single doses or multiple discrete doses of a drug, Vdarea correctly relates plasma concentration to amount of drug in the body at all times after distribution equilibrium is attained. Vdss, on the other hand, is a correct proportionality constant only during continuous intravenous infusion or at a single instant in time after discrete dosing. Furthermore, calculated values of Vdss are strongly dependent on the precise configuration of the initial distributional phase of the plasma concentration curve, which may be difficult or impossible to delineate because of variance arising from methodologic artefacts or unexplained causes. Such variance can lead to large nonphysiologic within- and between-individual variability in Vdss. Vdarea, on the other hand, is relatively independent or artefactual changes in the initial distribution profile. Finally, experimental observations indicate that elimination depends physiologically on distribution in the absence of changes in clearance, not the reverse. The relation of distribution and elimination holds whether the steady-state method or the area method is used to calculate Vd. Thus, Vdarea is a more reliable and generally valid descriptor of the extent of drug distribution than is Vdss.

Antipyrine↗

Reduced distribution and clearance of acetaminophen in patients with congestive heart failure.

Acetaminophen is a widely prescribed analgesic/antipyretic metabolized by hepatic glucuronide and sulfate conjugation. Twelve patients, 30-66 years of age, with stable Class III or IV congestive heart failure (CHF) and 12 healthy controls matched for age, sex, and weight received single 650-mg intravenous doses of acetaminophen. Pharmacokinetic variables were determined from multiple plasma acetaminophen concentrations measured by liquid chromatography during 12 h after the dose. Compared with controls, mean total clearance of acetaminophen was reduced in CHF patients (3.56 vs. 4.59 ml/min/kg, p less than 0.025), indicating reduced biotransformation capacity in this disease. Volume of distribution was also significantly reduced in CHF patients (0.85 vs. 1.02 L/kg, p less than 0.05). Since elimination half-life depends on both volume of distribution and clearance (both of which were reduced), the half-life was similar between groups (2.87 vs. 2.34 h, NS). Thus, hepatic conjugation of acetaminophen is impaired in CHF. The finding may also apply to other drugs biotransformed by conjugation.

Acetaminophen↗

Impairment of lidocaine clearance in elderly male subjects.

Six elderly male (65-75 years), seven elderly female (64-88 years), 15 young male (22-38 years), and nine young female (25-37 years) volunteers, all of normal body weight and clinically without cardiac or renal dysfunction, received a single 25-mg intravenous dose of lidocaine. Plasma concentrations of lidocaine were determined from blood samples drawn during 8 h following the lidocaine dose. Elimination half-life (t1/2) was markedly prolonged in elderly male subjects as compared with that in young male subjects (mean +/- SE: 2.70 +/- 0.21 versus 1.66 +/- 0.09 h; p less than 0.001). No difference in t1/2 was noted among female subjects (2.27 +/- 0.21 versus 2.07 +/- 0.07 h). Volume of distribution was greater in women than in men but was not influenced by age. Instead, prolongation in t1/2 in elderly men was the result of a highly significant decrease in total metabolic clearance (12.9 +/- 2.0 versus 19.8 +/- 1.5 ml/min/kg; p less than 0.05). No significant change in total metabolic clearance of lidocaine was noted between elderly and young women (18.3 +/- 2.0 versus 21.1 +/- 1.6 ml/min/kg). The findings suggest that in the elderly male patient without evidence of congestive heart failure or other coexisting chronic disease, the initial loading dose of lidocaine should be the same as for a young patient. However, to achieve comparable plasma concentrations and therapeutic effect during continuous infusion therapy, the elderly male patient should have the continuous infusion rate decreased by an average of at least 35%.

Adult↗

Pharmacokinetics of drugs in obesity.

Pharmacokinetic data in obesity are only available for a limited number of drugs. The rate or extent of drug absorption is not known to be altered by obesity which is not complicated by other medical disease. In contrast, drug distribution is in some instances significantly altered in obesity. Digoxin and bromsulphalein, both hydrophilic drugs, do not distribute into excess bodyweight over ideal bodyweight. However, antipyrine, paracetamol, aminoglycoside antibiotics and theophylline, all of intermediate lipid solubility, distribute to a limited extent into excess bodyweight over ideal bodyweight, although not as extensively as into ideal bodyweight. Benzodiazepines, halothane and enflurane, highly lipophilic agents, may distribute much more extensively into excess bodyweight over ideal bodyweight than into ideal bodyweight. This suggests some relationship between drug distribution and drug lipid-solubility in obese subjects. Whether these distributional changes in obesity will hold for other drugs is not currently known. Drug protein binding has not been demonstrated to be changed in obesity, data being presently available only for the basic drugs diazepam and desmethyldiazepam. Drug biotransformation in obesity is unchanged for oxidatively metabolised drugs studied to date. Paracetamol, the only metabolised drug which is conjugated for which pharmacokinetic parameters have been accurately determined in obesity, undergoes increased clearance in obese subjects.

Acetaminophen↗

Clinical pharmacokinetics of the newer benzodiazepines.

New benzodiazepine derivatives continue to be developed and introduced into clinical use. The pharmacokinetic properties of these newer drugs can best be understood by their categorisation according to range of elimination half-life and pathway of metabolism (oxidation versus conjugation). Clobazam and halazepam are long half-life (and therefore accumulating) anxiolytics metabolised by oxidation. Alprazolam and clotiazepam also are oxidised compounds but have short to intermediate half-life values and therefore produce considerably less accumulation. Temazepam and lormetazepam are hypnotic agents with intermediate half-lives but metabolised by conjugation. The most unique of the newer benzodiazepines are the ultra-short half-life (oxidised) compounds midazolam, triazolam and brotizolam, which are essentially non-accumulating during multiple dosage.

Alprazolam↗

The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.

12 obese patients, pair-matched with 12 normal subjects, received a single 1 mg oral dose of alprazolam. Nine similar subject pairs received a single 0.5 mg oral dose of triazolam. Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001), but there was no difference between the 2 groups for triazolam (117 vs 116L). Apparent oral clearance (not corrected for body weight) of alprazolam was lower, although not significantly so, in obesity (66 vs 88 ml/min), but for triazolam it was much lower in the obese (340 vs 531 ml/min, p less than 0.005). Elimination half-life, which is dependent on both Vd and clearance, was prolonged in obesity for alprazolam (22 vs 11h, p less than 0.001) due to the increase in Vd, and also for triazolam (4.1 vs 2.6 h, p less than 0.025) because of the decreased clearance. Plasma protein binding was unchanged in obese compared with control subjects for both alprazolam and triazolam. During long term administration alprazolam should therefore take longer to reach steady-state concentrations in obese patients but the final levels achieved should be no different than for patients of normal bodyweight, provided dosage is adjusted for ideal rather than total bodyweight. In contrast, triazolam has impaired clearance in obesity. However, if given once-daily it still would not accumulate with long term dosing due to its short half-life relative to the interval between doses.

Administration, Oral↗

Drug disposition in obese humans. An update.

Drug disposition for many drugs has now been studied in obese individuals and some general conclusions can be drawn. Absorption of drugs evaluated to date is unchanged due to obesity. Apparent volume of distribution is greatly increased for some drugs including most benzodiazepines, thiopentone, phenytoin, verapamil and lignocaine (lidocaine). Modest increases in volume of distribution have been noted for methylxanthines, aminoglycosides, vancomycin, ibuprofen, prednisolone and heparin. Distribution of digoxin, cimetidine and procainamide is unchanged in obesity. The mechanism for the increased distribution of some drugs and unchanged distribution of others in obesity is unclear at present. It may be in part due to the lipophilic character of the drug molecule; however, other complex and as yet poorly understood factors contribute to the variability in drug distribution in obese patients. Protein binding of drugs bound to albumin is not dramatically changed in obesity. In contrast, some studies report that drugs bound to alpha 1-acid glycoprotein (AAG) may have increased binding that is related to increased serum AAG concentration; however, this is not a consistent finding. Oxidative drug biotransformation is minimally changed in obesity with the exceptions of ibuprofen and prednisolone, for which clearance increases as a highly correlated function of total bodyweight. Drug conjugation uniformly increases as a function of bodyweight in obesity, with paracetamol (acetaminophen), lorazepam and oxazepam having been studied. Drug acetylation may be unchanged in obesity, with only procainamide evaluated at this time. High clearance drugs, including lignocaine, verapamil and midazolam, have no change in clearance in obese individuals compared to normal bodyweight controls. Renal clearance of drugs is little changed for some drugs evaluated (digoxin, cimetidine), and increased for others (aminoglycosides, unmetabolised procainamide). Characterisation of appropriate animal models of obesity is underway to clarify the mechanisms for these in vivo pharmacokinetic observations in obese man. Two models, the Zucker obese and the obese cafeteria-fed male Sprague-Dawley rat, have provided preliminary physiological pharmacokinetic data with evaluations of theophylline, phenobarbitone and verapamil.(ABSTRACT TRUNCATED AT 400 WORDS)

Aminoglycosides↗

Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.

Previously, we have demonstrated in vivo, in humans, nonlinear diltiazem disposition with an elimination half-life 50-100% greater after chronic diltiazem as compared to single-dose diltiazem administration. At least two metabolites, desmethyldiltiazem (MA) and desacetyldiltiazem (M1), accumulate significantly in human plasma during chronic diltiazem administration. To test the hypothesis that nonlinear diltiazem accumulation is associated with inhibition of biotransformation, we studied diltiazem disappearance during incubation with a number of its identified metabolites in an isolated rat hepatocyte system. Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM. These apparent ki values are similar to those derived for diltiazem-mediated inhibition of other drug substrates such as antipyrine, the clearance of which is inhibited by diltiazem in vivo in humans. Nonlinear diltiazem accumulation in vivo may be explained in part by progressive metabolite accumulation, particularly MA, which results in the inhibition of parent drug diltiazem biotransformation.

Animals↗